The markets refuse to forgive Infinity
The company’s second foray with a PI3K inhibitor shows signs of additive activity, but investors punish it all the same.
Biopharma’s ballooning licensing deal bill
Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.
The search for a better Faslodex continues
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
The moral battle lines are drawn in Alzheimer’s
Biogen goes on the offensive against “misinformation” and a media assault, but Roche says patients want clinical benefit, “not imaging”.
Roche takes the Tim-3 battle to Novartis
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
